What happened?
Vaxart , the biotech creating tablet-based vaccines, jumped 78.2% last month according to S&P Global Market Intelligence. The increase recovered some of the ground it lost after Phase 1 data from its COVID-19 vaccine disappointed investors in early February. Shares closed the month at $10.78.
So what?
About three months ago, investors bid shares of Vaxart higher in anticipation of results that it failed to deliver. The company kicked off May by reporting disappointing earnings before the bell on Monday May 3. That triggered a sell-off that erased much of April’s gains. Despite the share volatility, the company plows forward.
Now what?
Management announced it will advance its VXA-CoV2-1 tablet vaccine into Phase 2. The company also plans to advance its norovirus vaccine through studies of a booster dose and in the elderly population.
Vaxart continues to trade on its potential. However, that potential coming to fruition is important for the U.S. to beat the pandemic. The company’s own study suggested 19 million vaccine-skeptical Americans — many in underserved demographics — would get inoculated if the method of administration was pill rather than injection.
Should you invest $1,000 in Vaxart right now?
Before you consider Vaxart you’ll want to hear this.
Investing legends and Motley Fool Co-founders David and Tom Gardner just revealed what they believe are the 10 best stocks for investors to buy right now… and Vaxart wasn’t one of them.
The online investing service they’ve run for nearly two decades, Motley Fool Stock Advisor, has beaten the stock market by over 4X.* And right now, they think there are 10 stocks that are better buys.